November 2017  
Topics that resonated in conversations and surgeon presentations at NASS included advancements in additive manufacturing or 3D printing, replacement or coating of traditional PEEK and the adoption of robotics and navigation. While larger spine companies are already pursuing these technologies, we noticed that the mid-sized down to startups are also prioritizing these initiatives.

The Orthopaedic Trauma Association convened for its annual meeting, and many of the common themes in surgeon voices and research focused on complex fractures and complications from fractures. We recap with Dr. McKee, Surgeon Chair of OTA.

December issue

December issue


Following weather events, oft-cited "softness" in U.S. spine procedures (to wit: volume is reportedly low this year) and the enactment of a price ceiling on knee devices in India, some--like ConforMIS, ConMed, DePuy Synthes, Exactech, Integra, K2M and Stryker--noted modest reductions in revenue, but not enough to restate full-year guidance.
Titan Spine entered the Australian market and announced first surgeries completed in the region with Endoskeleton® interbody fusion devices and surface technology.
The company's technologies are based on a faceted threadform that reportedly demonstrates superior performance vs. conventional helical designs. 
The project, "EZH2 inhibitors as endoprosthetic device coatings that induce osteogenesis and promote implant osseointegration," seeks to identify drug options for use in hip and knee implant surface coatings. The combination of drug and device is expected to support integration of existing bone into the implant, to reduce complications and potentially add to the life of an implant.
Mortise Medical is a medical device startup incubated and operated by Surgical Frontiers. SyndesMetrics is designed to support predictable/repeatable anatomic reduction, restoration of physiological motion and restoration of ankle stability.
DT MedTech received FDA 510(k) clearance to market the Hintermann Series H2™ Total Ankle Replacement, a semi-constrained cemented prosthesis for primary or revision surgery. Limited launch is slated for late 4Q17, ex-U.S., as it has already secured CE Mark Approval.
Medacta received FDA 510(k) clearance and completed first knee revision procedures with 3DMetal™ Tibial Cones. The cones are slated for 1Q18 launch.

You may also benefit from supply chain/commercialization-centric content contained in BONEZONE. 

    - Confirm your print subscription here

Enter code "SOLUTIONS" at  checkout to save $49. That's $0 for OEMs and $126 for all others.